There are currently no approved treatments or vaccines for the novel coronavirus, which has infected 2.18 million globally, according to a Reuters tally, and remdesivir is one of the treatments that has captured investor attention. Gilead said the totality of the data from the trial needed to be analyzed, and expects to report results from a study in severe COVID-19 patients at the end of the month, and data from other trials in May. The report said the University of Chicago Medicine Hospital was seeing rapid recoveries in fever and respiratory symptoms in patients with severe COVID-19 in …read more
Source:: Yahoo Finance
